Peter Nørkjær Laursen

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Filip K. Knop, Vanita R. Aroda, Ruben D do Vale et al. · The Lancet · 2023 · 379 citations

Pharmacy, Pharmacology, Pharmacotherapy +4

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Leigh Perreault, Melanie J. Davies, Juan P. Frías et al. · Diabetes Care · 2022 · 79 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Relationship between patient presentation and morphology of coronary atherosclerosis by quantitative multidetector computed tomography

Martina Chantal de Knegt, Andreas Fuchs, Michael Huy Cuong Pham et al. · European Heart Journal - Cardiovascular Imaging · 2018 · 32 citations

Medicine, Cardiology, Radiology +17

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Lua Wilkinson, Thomas Holst‐Hansen, Peter Nørkjær Laursen et al. · Obesity · 2023 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Importance of elevated heart rate in the very early phase of ST-segment elevation myocardial infarction: Results from the DANAMI-3 trial

Lars Nepper‐Christensen, Jacob Lønborg, Kiril Aleksov Ahtarovski et al. · European Heart Journal Acute Cardiovascular Care · 2018 · 15 citations · Full text

Medicine, Cardiology, Internal Medicine +17